Cyclo Therapeutics, Inc. financial data

Location
Gainesville, FL
Fiscal year end
31 December
Latest financial report
10-K/A - Q4 2023 - 18 Dec 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 61% % -31%
Quick Ratio 2% % -51%
Return On Equity 750% % -78%
Return On Assets -326% % 22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28,768,055 shares 27%
Common Stock, Shares, Outstanding 28,768,055 shares 49%
Common Stock, Value, Issued $0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 28,729,641 shares 77%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $15,974,463 USD 21%
Costs and Expenses $25,501,947 USD 27%
Operating Income (Loss) $24,688,719 USD -27%
Nonoperating Income (Expense) $110,951 USD 32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $24,799,670 USD -28%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $24,799,670 USD -28%
Earnings Per Share, Basic -1 USD/shares -102%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $928,010 USD -48%
Accounts Receivable, after Allowance for Credit Loss, Current $187,682 USD -38%
Inventory, Net $236,110 USD 13%
Assets, Current $3,256,608 USD -41%
Property, Plant and Equipment, Net $19,988 USD -51%
Operating Lease, Right-of-Use Asset $26,636 USD -41%
Assets $5,253,902 USD -6.1%
Accounts Payable, Current $5,023,095 USD
Liabilities, Current $18,720,099 USD 183%
Operating Lease, Liability, Noncurrent $7,143 USD -74%
Retained Earnings (Accumulated Deficit) $103,013,942 USD -32%
Stockholders' Equity Attributable to Parent $13,473,340 USD -1180%
Liabilities and Equity $5,253,902 USD -6.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,182,133 USD -41%
Net Cash Provided by (Used in) Financing Activities $69,281 USD -102%
Common Stock, Shares Authorized 250,000,000 shares 400%
Common Stock, Shares, Issued 28,768,055 shares 49%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,251,414 USD -895%
Interest Paid, Excluding Capitalized Interest, Operating Activities $756 USD -56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,981,254 USD -29%
Operating Lease, Liability, Current $20,116 USD 12%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $89,537,725 USD 16%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,177 USD -55%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%